Magnesium is a commonly used remediation for NLC, particularly in Latin America and Europe. 4 Its effectiveness in treating NLC was first demonstrated in a double-blind, randomized, placebo-controlled study of pregnant women. 9 Subsequent trials-2 crossover studies 10, 11 and a placebocontrolled trial of magnesium infusion 12 -did not show significant benefit by magnesium citrate supplements for NLC in older adults. 13 However, none of the published studies investigated oral magnesium oxide. Magnesium is an intracellular cation, and its serum concentrations (only about 1% of total body magnesium) may not accurately mirror magnesium status. 14 A recent study investigated the effect of supplemental oral magnesium oxide, vs magnesium citrate, on intracellular magnesium levels in healthy subjects. 15 Oral magnesium oxide significantly increased intracellular magnesium levels compared with magnesium citrate. On the basis of this observation, we initiated a prospective clinical trial to test the hypothesis that magnesium oxide supplementation may reduce the frequency and severity of NLC and subsequently improve quality of life and quality of sleep of older adults.
Methods

Design Overview
This randomized, double-blind, placebo-controlled trial investigated the effect of magnesium oxide supplementation on NLC. Initially, participants underwent 2 weeks of eligibility screening without treatment, during which they documented all episodes of NLC, followed by 4 weeks of treatment. The primary end point was the effect of magnesium oxide supplementation on the frequency of NLC. Secondary objectives were severity and duration of NLC, quality of sleep, and quality of life.
Setting and Participants
The study took place at community clinics of Clalit Health Services (CHS) in northern Israel, from February to October 2013. We used advertisements in CHS clinics, the local media, and pharmacies to invite individuals suffering from NLC to participate in the trial. Initially, study stuff interviewed interested patients who had called to determine their eligibility. We informed respondents who were currently taking magnesium supplements and expressed interest in participating that they could enroll if they agreed to stop taking the supplements at least 10 days before enrollment. Thereafter, at an inperson, baseline evaluation visit we provided a comprehensive description of the study rationale and process. After confirming that each candidate experienced NLC, described as a painful, involuntary contraction of muscles occurring at rest, mostly at night, and causing a palpable knot in the muscle, the participant signed an informed consent. Inclusion criteria were community-dwelling individuals, age older than 21 years, 4 or more documented episodes of NLC during the 2-week screening phase, and insurance with CHS. Exclusion criteria were pregnancy, current treatment with quinine, concurrent intake of a magnesium supplement, renal failure (defined as serum creatinine level >2 mg/dL [to convert to micromoles per liter, multiply by 88.4]), and major neurological diseases such as amyotrophic lateral sclerosis, multiple sclerosis, paraplegia, or quadriplegia.
Randomization and Intervention
We randomly allocated participants in a 1:1 ratio to receive either magnesium oxide (inorganic granular magnesium complex, composed of magnesium oxide and magnesium oxide monohydrate 865 mg, providing 520 mg of free elemental Mg 2+ [magnesium]) or a similar-looking placebo to be taken orally, once daily at bedtime for a period of 4 weeks.
Identical-looking capsules, containing either magnesium oxide or placebo, were prepacked in identical bottles and consecutively numbered prior to the study initiation. We generated a randomization schedule, derived from a computergenerated randomization procedure of numbers from 1 to 220, in blocks of 10. The randomization scheme was generated by using the website Randomization.com (http://www .randomization.com). We assigned eligible participants sequential numbers according to the randomization schedule, and they received the corresponding numbered bottle of capsules. Both patients and researchers were blind to the treatment allocation. The manufacturer provided the study participants reimbursement of travel expenses (of up to the equivalent of $50) that was given to each participant at the final meeting after retrieving the medication bottle.
Outcomes and Follow-up
The primary outcome was the mean difference in effect of magnesium oxide, compared with placebo, on the frequency of NLC. Secondary objectives were severity and duration of NLC, quality of sleep, and quality of life.
We measured the primary outcome by comparing the change in the mean number of episodes of NLC per week, during the 2-week screening and the 4-week treatment phases, between the magnesium oxide and placebo groups. Secondary outcomes were changes in the severity and duration of NLC, in quality of life, and in quality of sleep. We collected patients' demographic and clinical characteristics at their baseline visit through self-report questionnaires.
Outcome Measurement Tools
We measured the number, severity, and duration of NLC as recorded daily by the study participants in a designated, structured sleep diary. The Nocturnal Cramps Sleep Diary (NCSD) (eAppendix in Supplement 1) is a combined adaptation of the "assessment, Espie diary form," 16 which is based mainly on Espie's book, 17(p17) and the Two Week Sleep Diary, 18 designed for the purpose of the present study. Throughout this 6-week period, participating individuals documented daily all episodes of NLC in the NCSD. They reported every morning in the diary the frequency (ie, the absolute number), duration, and severity of NLC. The severity of pain experienced during NLC was recorded in the diary on a numbered scale of 0 to 10 (0 = no pain, 10 = intolerable pain). Participant assessed and reported the duration of each cramp in minutes. The Short Form (36) Health Survey (SF-36) measured quality of life.
19 This 36-question survey yields an 8-scale profile of functional health and well-being, as well as psychometrically based physical and mental health summary measures and a preference-based health utility index. This generic measure has demonstrated effectiveness in surveys of general and specific populations, in comparing the relative burden of diseases and in differentiating the health benefits produced by a wide range of different treatments. 20 It has been validated in Hebrew. 21 We used the Pittsburgh Sleep Quality Index (PSQI) to measure quality of sleep. 22 The PSQI is a standardized selfadministered questionnaire that assesses subjective sleep quality over the previous month. The PSQI comprises 19 selfrated questions grouped into 7 component scores. Each score weighs equally ona0t o3point scale. The 7 component scores are totaled to provide a global PSQI score. The global score ranges from 0 to 21. A global score of 5 or more indicates poor sleep quality: the higher the score, the worse the quality of sleep. The PSQI has been validated in Hebrew. 23 We measured quality of life and quality of sleep twice: at enrollment and within 1 week after the end of the treatment period of each participant.
Outcomes and Adherence Ascertainment
During the screening and treatment phases of the study (2 and 4 weeks, respectively), the study participants filled in the NCSD daily, at home. To increase adherence and proper monitoring and documentation of sleep and NLC events, a daily text message reminder was delivered every morning to each participant (all of them had a mobile telephone). Additionally, twice a week we made a telephone call to each study participant inquiring about possible adverse events and encouraging them to take the study treatment and to fill in the diary every evening and morning. We intentionally placed 32 capsules in each medication bottle, 4 more than the needed 28 capsules for the 4 weeks of the intervention. On the final visit, we asked all participants to bring the study medication bottles, with the remaining capsules, and counted them. We instructed all participants to avoid consumption of vitamin and mineral supplements during the study.
Interim Analysis and Guidelines for Study Termination
The study protocol (Supplement 2) included a preplanned blinded interim analysis of efficacy or futility when outcome results were available for approximately half of the anticipated number of participants. We submitted this analysis to an appointed independent data reviewing and monitoring committee that reviewed the interim results. The committee's role was to monitor the primary outcome, ensure the safety of patients, make recommendations to continue or alter the study design, and determine the necessity of early termination of the trial due to efficacy, harm, or futility.
Ethical Issues
The study medication is a freely available, over-the-counter food supplement. We also recruited individuals who were taking magnesium supplements before enrollment if they wanted to participate and freely agreed to stop taking them. This was possible because they stopped taking the supplement at least 10 days before enrollment. The Community Independent Review Board of CHS approved the study. All participants provided written informed consent prior to any study procedure.
Statistical Analysis
We estimated that 110 participants would be needed in each group to achieve 80% power to detect a treatment difference at a 2-sided .05 significance level if the true difference between treatments is 1 (difference in mean change between treatment groups) NLC per week. This was based on the assumption, and the results reported by Roffe et al, 11 that the standard deviation of the mean number of NLC per week is 3.
24
We performed all data analyses according to the intentionto-treat principle, and the analysis, data collection, and processing were blinded with respect to treatment group assignment. Randomized participants who did not complete the study were included in their assigned study groups for the primary analysis. We used multiple imputations from the screening values of each participating individual to replace missing values during the treatment phase. Treatment effects for primary and secondary outcome variables in the study were evaluated using a repeated-measure analysis, comparing the individual differences between treatment groups by treatment phase (interaction effect). Thus, we defined the trial outcome as the difference in the mean change from the screening to the treatment phase in the number of NLC between the treatment groups, that is, magnesium oxide vs placebo. We performed a similar comparison with the data on severity and duration of NLC. We measured quality of life and quality of sleep twice: at enrollment and within 1 week after the end of the treatment period of each participant.
We used the Bonferroni approach 25 as an adjustment for multiple comparisons for the SF-36 subscale measures, resulting in a critical P value of .006 (according to the formula of desired P value [.05] divided by the number of comparisons [8] ). Additionally, we conducted a 2-way (group over time) trend analysis for the primary outcome, examining for possible trends in treatment effects across time.
We compared baseline characteristics between the groups using the χ 2 test for categorical variables and the t test for continuous variables. Models evaluating possible modification effects of baseline characteristics on outcomes were conducted by including terms of interactions between the 2 groups and by examining the effect of each of these variables on the study outcomes using 2-way analysis of covariance. We conducted all analyses using SPSS software, version 21 (IBM SPSS Statistics for Windows). Both patients and researchers were blind to the treatment allocation throughout the study until the decision on early termination.
Results
From February through October 2013, 166 individuals responded to the advertisements and were screened for eligibility for the study. Of these 166 candidates, 94 (56.6%) individuals fulfilled the study's inclusion criteria and underwent randomization. The study protocol was completed fully by 88 (93.6%) of the randomized individuals ( Figure 1) . Baseline characteristics of the participating individuals were similar between the treatment groups ( Table 1 ). The characteristics of those who completed the study protocol did not differ significantly from the characteristics of those who did not.
The mean numbers of NLC per week during the 2-week screening period were similar between the groups ( Table 2 ). The mean (SD) number of NLC per week decreased significantly from the screening to the treatment phase, by 48.4% (41.2%) and 29.5% (64.8%) for the magnesium oxide and placebo groups, respectively (P < .001 for the change within each group). However, there was no statistically significant difference in the primary outcome of change in mean (SD) NLC frequency per week between the magnesium oxide and placebo groups: −3.41 (4.05) and −3.03 (4.53), respectively, a difference between the groups of −0.38 (0.48) NLC per week (P = .67). A sensitivity analysis to assess the possible effect of missing data yielded results that were essentially identical to those presented in Table 2 . We observed similar results in the analysis of the secondary outcomes, as presented in Table 2 . The effect on severity and duration of NLC was also not significant (P = .38 and P = .30, respectively). Furthermore, no statistically significant differences were observed between the treatment groups in the changes in scores from enrollment to the end of the treatment period, in the total SF-36 score, the scores of any of its components, and in the PSQI global score (Table 2) . Additionally, to allow the combination of our results in the meta-analysis, we calculated the minimum clinically important difference (ie, the number of people obtaining 25% reduction in NLC) and obtained 75% (n = 36) and 63% (n = 29) in the magnesium oxide and placebo groups, respectively, a nonsignificant difference (P = .21).
We tested for interaction terms and found no interaction effect between any of the baseline characteristics of the participants examined and any of the outcomes. Additionally, we conducted a repeated-measures analysis of variance for trend analysis with specific contrasts that compared the differences in mean values of outcome variables during the screening and treatment periods (5 points of time). The analysis examines the trend of change over time for the entire sample and within each group, while controlling the cumulative statistical error of correlated comparisons (P = .86 for trend) ( Figure 2 ). We conducted a pill count in the 88 participants who completed the study protocol fully. The number of capsules in the retrieved bottles ranged from 2 to 6 (mean of 4.1 per participant) and was explained by the participants to be due to forgetfulness (twice in 4 cases and once in 3) and continuation for an additional 2 days (1 participant).
Adverse Events
Six serious adverse events (hospitalization) occurred during the study period, 2 during the screening phase and 4 during the treatment phase, 2 in each treatment group. All hospitalizations were for concurrent medical problems that are frequent in elderly individuals. None was assessed to be related to the study medication use. Additionally, minor adverse effects, mostly gastrointestinal, occurred in 14 and 13 participants in the magnesium oxide and placebo groups, respectively.
Study Termination
On April 1, 2014, we submitted the results of 94 participants (43% of the 220 planned) for a blinded interim analysis. The results showed that magnesium for the treatment of NLC is safe but probably not more effective than placebo. With 43% of the study population recruited, the chances that the differences between the groups in the outcomes assessed would change and become significant were low; thus, at this stage the committee recommended that the study be discontinued due to lack of efficacy.
Discussion
This randomized clinical trial did not confirm our hypothesis that magnesium oxide supplementation is more effective than placebo in reducing NLC in community-dwelling individuals. To our knowledge, this is the first study in which magnesium oxide, rather than magnesium citrate, was tested as prophylaxis for NLC. Despite the recent evidence of improved intracellular absorption, 15 magnesium oxide supplementation was not significantly better than placebo. There was no evidence that the effect of treatment was dependent on demographic or clinical characteristics of the participants, including the use of magnesium supplements before enrollment. Magnesium deficiency can result from various etiologies, and elderly people are particularly at risk because of the combination of chronic diseases, poor nutrition, decreased absorption of magnesium, and increased renal exertion. 27 As magnesium deficiency is associated with neuronal excitability and enhances neuromuscular transmission, 4,28,29 and because its substitution has been shown to be effective in eclampsiarelated seizures, 30,31 a number of researchers have suggested a possible beneficial role of magnesium supplementation in NLC. Some effectiveness was indeed demonstrated in a study of pregnant women. 9 However, subsequent trials in nonpregnant individuals did not demonstrate effectiveness of magnesium supplementation as prophylaxis for NLC in the general population.
13,32
The present study is based on self-reported outcomes. The prospective nature and the conduct of a 2-week screening period, during which individuals were instructed to record data daily, in a diary, helped mitigate recall bias and screened for participants who would not adhere to the study protocol. Telephone calls and text messages during the screening and treatment phases presumably contributed to the adherence to the study protocol and the consumption of the study medication, as was reflected in the pill count and the low dropout rate.
Limitations
Limitations of the study include the modest number of participants, who were mostly elderly individuals, and the intervention period of only 4 weeks. Participants were self-selected individuals who volunteered to participate, introducing certain selection bias. However, all reported trials were smaller or of similar size and duration. Given the intensive follow-up and meticulous event adjudication, coupled with the patientcentered approach, it seems unlikely that a significant beneficial effect was missed. This led the independent data reviewing and monitoring committee to recommend early termination of the study after 94 participants due to lack of efficacy.
Conclusions
Previous research shows inconclusive results concerning the efficacy of magnesium therapy in the treatment of NLC in general populations due to the relatively low methodological qualities of the trials. 32 Nevertheless, magnesium supplements are widely marketed, and purchased, worldwide as a preventive treatment for muscle cramps. The statistically significant decrease in the frequency of NLC following treatment with both magnesium and placebo may explain the perceived benefit experienced by magnesium users. However, this randomized clinical trial suggests that magnesium oxide supplementation is no better than placebo for NLC. It appears unlikely that older adults with NLC will significantly benefit from magnesium supplementation. Values at screening phase refer to the mean number of nocturnal leg cramps per week during the 2 weeks of screening; error bars represent standard errors. a The answer to this question defines the primary outcome of the study of frequency of NLC; we counted the number of NLC events, during each week of the entire study, for each participant; for the statistical analysis the weekly means were calculated for each treatment group during the two weeks screening and the four weeks treatment phases.
Research Original Investigation
b The answer to this question defines the secondary outcomes of the study; to assess severity of NLC we calculated the weekly average of severity of pain of the reported events (sum of pain severity in all NLC divided by their number); for the statistical analysis the weekly means were calculated for each treatment group during the two weeks screening and the four weeks treatment phases.
c Similar assessment, as was done for severity of pain, was used for the duration of NLC. 
SAMPLE SIZE AND TREATMENT GROUPS:
A total of 220 subjects (200 subjects adjusted for about 10% withdrawal rate) will randomly be assigned to two study arms employing a 1:1 randomization scheme. Each randomized individual will be given once daily either MAGNOX 520 ® or a similarly looking placebo for a treatment period of 4 weeks.
CLINICAL TRIAL DURATION:
Two weeks of eligibility screening followed by 4-week doubleblind treatment.
INCLUSION CRITERIA:
Signed informed consent before any procedure or assessment is done.
Age over 21 years old.
Over 4 episodes of documented NLC during 2 weeks of eligibility screening (for the treatment phase).
Insured by Clalit Health Services (CHS).
Hebrew speaking
EXCLUSION CRITERIA:
Pregnancy Currently taking Quinidine or Magnesium additive
Renal failure -serum creatinine more than 2 mg/DL. If the result is near these creatinine limits (i.e. serum 1.5-2) a second analysis will be done near the study enrollment.
Major neurological disease-ALS, MS, Paraplegia or Quadriplegia. 
DOSAGE OF INVESTIGATIONAL PRODUCT
CONTROL PRODUCTS:
Similarly looking placebo.
MODALITIES OF DRUG ADMINISTRATION:
Oral administration once daily for 4 weeks. The primary assessment will compare outcomes between MAGNOX 520 ® and placebo treated individuals during a treatment period of 4 weeks.
MAIN STUDY PARAMETERS:
Efficacy
CLINICAL TRIAL PROCEDURES:
The number, severity and duration of NLC will be measured daily as documented in a designated, structured sleep dairy -The Nocturnal Cramps Sleep Diary (NCSD). Quality of life and quality of sleep will be assessed by SF-36 and PSQI questionnaires, respectively, to be completed twice -at enrolment and within one week of the end of the treatment period.
STATISTICAL METHODS:
The study was designed as a proof-of-concept study, single-center, prospective, randomized, double The difference in the change in quality of sleep (measured by PSQI at enrolment and after the treatment period) between the MAGNOX 520 ® and the placebo treated individuals;
SAMPLE SIZE RATIONALE:
As this is a proof-of-concept study, the difference in the number of episodes of NLC documented in the NCSD, as compared between the MAGNOX 520 ® and the placebo treated individuals, during a treatment period of 4 weeks, will serve as the sole primary efficacy end point for this study.
We calculated that a total of 200 patients will needed, for this two-treatment parallel-design study, to achieve a probability is 90 percent that the study will detect a treatment difference at a two-sided 0.04 significance level, if the true difference between treatments is 3.801 (difference in means between treatment groups) NLC events. This is based on the assumption that the standard deviation of the mean number of NLC events is 8.
STATISTICAL METHODS:
In order to examine the homogeneity between groups regarding outcome measures at enrollment and bio-demographic measures (study vs. control) a t-test will be conducted with group as independent variable, and study outcomes at enrollment and biodemographic measures as dependents. Bio-demographic nominal scale variables will be tested using Chi square test. At the end of the study a composed subscales of the dependent variables will be computed, as follows: SF36 questionnaire, PSQI questionnaire, and number, severity and duration of NLC according to daily dairy. All the subscales will be computed according to instructions in the study tools manuals. 2-way (group X time) trend analysis will be conducted looking for possible trend of change in treatment effect across time. The effect of the study will be examined using repeated measures (RM) ANOVA. The repeated measures analysis will compare the difference scores of each of the dependent measures between study and control groups. In order to explore possible effects of bio-demographic variables a 2-way/ 3-way RM ANOVA with group X independent factors (for example: gender, age) will be conducted. Magnesium is an intracellular cation; only 1 percent is extracellular, 31 percent are intracellular and 67 percent in bone matrix. Consequently, magnesium blood level is only a rough index of total body magnesium stores and deficiency in magnesium can be present when serum levels are within normal range.
Magnesium is required for the activation of important enzyme system involving ATP and the metabolism of protein, carbohydrates, fat and nucleic acids, for normal cell membrane function and for neuromuscular transmission. Magnesium plays an important role in maintaining the sodiumpotassium gradient across cell membranes and regulates the muscle cell function, cardiac rhythm, vasomotor tone, neuromuscular function and parathyroid hormone metabolism.
Magnesium is absorbed primarily in the jejunum and ileum. Food products rich in magnesium are green vegetables, seed grains, nuts, peas and beans. Magnesium consumption in the world is in decline, mostly because of over purification processes in the food industry. 13, 14, 15 Excess magnesium in the blood is freely filtered in the kidneys; therefore toxicity from dietary sources alone is rare. Minor reported side effects were abdominal discomfort and diarrhea occurring in magnesium and placebo-treated patients. 10, 11 Overdose with magnesium supplements is possible, In a recent study researchers investigated the impact of supplemental oral magnesium citrate versus Magnesium Oxide Monohydrate on intracellular magnesium levels. 16 They found that oral Magnesium Oxide Monohydrate, rather than magnesium citrate, significantly increased intracellular magnesium levels in healthy subjects.
Hypothesis
Magnox 520 ® may reduce the number and severity of NLC; an improvement in the quality of life and quality of sleep may ensue.
Objective:
To assess the effect of treatment with Magnox 520 ® , as compared with placebo, on frequency and severity of NLC, quality of sleep and quality of life.
Methods
Study design:
A prospective, randomized, double blind, placebo controlled clinical trial.
Participants:
Two hundred individuals afflicted by NLC will be recruited for the study.
Inclusion criteria: 1. Age> 21 years old.
2. Over 4 episodes of documented NLC during 2 weeks of eligibility screening.
3. Insured by Clalit Health Services (CHS).
Hebrew speakers
Exclusion criteria: 
Outcomes measurement in each participant
The number, severity and duration of NLC will be measured daily as documented in a designated, structured sleep dairy; The Nocturnal Cramps Sleep Diary (NCSD).
Quality of life and quality of sleep will be assessed by SF-36 and PSQI questionnaires, respectively, to be completed twice -at enrolment and within one week of the end of the treatment period.
(*A detailed, referenced, description of the study measurement tools is provided in the appendix)
Outcome and compliance ascertainment During the treatment phase of the study (4 weeks) a daily structured sleep dairy will be filled by the participating individuals; we will initiate a daily Short Message Service (SMS) reminder and 1-2 weekly telephone calls in order to ensure compliance and proper monitoring and documentation of sleep and NLC events. The degree of pain will be recorded in the dairy on a scale of 0 to 10 (0=no pain, 10= intolerable pain). Capsules count will be conducted upon the medication bottles retrieval at the end of the treatment phase of the study in each participating individual.
Interim analysis and stopping guidelines
A blinded interim analysis of efficacy will be performed when outcome results for 50% of the anticipated number of participants will be available. It will be presented to an independent data reviewing and monitoring committee appointed to monitor the safety and scientific integrity of the study, and to make recommendations regarding the early termination of the trial for efficacy, for 
Ethical Issues
The study medication is a freely available, over the counter (OTC), supplement. Participating individuals will sign an informed consent form approved by the Independent Review Board (IRB)
of Meir Medical Center (see Enrolment and Eligibility Screening section below), prior to any study procedure. Informed consent will be obtained by GCP certified physicians.
Additional Ethical Comments:
Those subjects who respond to the advertisements have implicitly given their permission to be contacted by doing so. Consequently, as an optional pre-screening procedure, when a potential participant calls the research center, it is ethically acceptable to receive an oral approval to extract the patient's latest Creatinine measurement from the medical records, in order to prevent unnecessary invitation and disappointment. We specifically ask the CHS Community IRB for an approval for this pre-screening procedure.
Individuals, that report at enrollment that they are currently taking Magnesium supplements, cannot be included in the study according to the exclusion criteria. However, since the study starts with a two weeks screening phase (without treatment), if this individuals express their willingness to stop taking the Magnesium supplement and by that wish to be able participate in the study, this exclusion criteria is no longer valid in this particular subjects. Consequently, they may be enrolled in the study if they freely wish to do so. We believe that this is ethically acceptable since Magnesium supplement is a freely available OTC and there is no evidence that Magnesium supplement is beneficial.
Recruitment and Follow Up:
Outreach Patients suffering from NLC will be recruited, by self selection through advertisements in CHS clinics, local media and pharmacies. Patients calling the research center will be asked, as a optional pre-screening procedure, to provide an oral approval to extract their latest Creatinine measurement from the medical records, in order to prevent unnecessary invitation and disappointment. This oral consent is given freely and is not a condition to proceed in the study.
Patient taking currently Magnesium OTC supplement will have to agree to stop taking this OTC in order to be included in the study. Eligible individuals will be invited for enrollment. A comprehensive description of the study rational and process will be provided and, after questioning and elaboration as requested by the candidate, a signed informed consent will be obtained. Each candidate will then undergo 2 weeks of primary eligibility screening during which he will be asked to report all episodes of NLC by filling the NCSD. Individuals with more than 4 NLC episodes during 2 week will be eligible to start the treatment phase of the study and receive the study medication.
Enrolment and Eligibility Screening
Randomization Eligible participants will be randomly assigned, following simple randomization procedure (computerized random numbers), to one of the two treatment groups. Participants will be assigned a sequential order number and received the capsules in the corresponding numbered pre-packed bottles.
Treatment Phase
Each randomized individual will be given once daily either MAGNOX 520 
Expected side effects:
Minor reported side effects were abdominal discomfort and diarrhea occurring in magnesium and placebo-treated patients.
10,11
Adverse Events reporting:
Participants will be asked about any adverse event (AE) during the treatment phase of the study by 1-2 weekly telephone. Any adverse event will be reported to the PI immediately by filling an AE form. Any serious adverse event (SAE) will be reported immediately by telephone to the PI.
Statistical methods:
Version 3 We estimated that 110 participants would be needed in each group to achieve 80% power to detect a treatment difference at a two-sided 0.05 significance level, if the true difference between treatments is one (difference in means change between treatment groups) NLC per week. This was based on the assumption, and the results reported by Roffe et al, that the standard deviation of the mean number of NLC per week is three.
In order to examine the homogeneity between groups regarding outcome measures at enrollment and bio-demographic measures (study vs. control) a t-test will be conducted with group as independent variable, and study outcomes at enrollment and bio-demographic measures as dependents. Bio-demographic nominal scale variables will be tested using Chi square test. At the end of the study a composed subscales of the dependent variables will be computed, as follows:
SF36 questionnaire, PSQI questionnaire, and number, severity and duration of NLC according to daily dairy. All the subscales will be computed according to instructions in the study tools manuals.
2-way (group X time) trend analysis will be conducted looking for possible trend of change in treatment effect across time. The effect of the study will be examined using repeated measures (RM) ANOVA. The repeated measures analysis will compare the difference scores of each of the dependent measures between study and control groups. In order to explore possible effects of biodemographic variables a 2-way/ 3-way RM ANOVA with group X independent factors (for example: gender, age) will be conducted.
Role of Sponsor, Investigators and Manufacturer
Sponsor and study monitor: Uzi milman MD (UM) Nevepharma LTD, in the preparation of the study protocol, the design, conduct, data analysis and report of the study.
Individuals will be recruited by the researchers that will obtain an informed consent; study procedures, conduct, follow up and analysis will be contracted directly by the manufacturer with Sarid institute INC. Process and analysis results will be reported directly to the researchers
Funding:
Study capsules (MAGNOX 520 TM or placebo) will be supplied by the manufacturer, Nevepharma LTD. All the needed research resources, as described in the study protocol MgNLC ver 003, (including statistical analysis and consultation, a research assistant and the study forms and coordination) will be provided to the study researchers by Sarid Institute INC contracted directly with Nevepharma LTD. These resources and the study medication will be available for the researchers free of any charge and without any involvement of Nevepharma LTD in the preparation of the study protocol, the design, conduct, data analysis and reporting of the study. The sponsor and investigators will not receive any personal or any other funding from the manufacturer, Nevepharma LTD. Participating individuals will be offered travel expenses reimbursement of 50$ (200 NIS).
